Neurocutaneous Disorder Market Research Report – Forecast to 2023

Report / Search Code: MRFR/HC/4481-HCRR
Publish Date: October, 2018

Price

<table>
<thead>
<tr>
<th>1-user PDF</th>
<th>$4450.0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Enterprise PDF</td>
<td>$6250.0</td>
</tr>
</tbody>
</table>

Description:

Global Neurocutaneous Disorder Market Research Report: By Type (Tuberous Sclerosis (TS), Neurofibromatosis (NF), Sturge-Weber Syndrome, A-T, VHL), by Diagnosis (MRI, CT, EEG), End-User (Hospitals & Clinics, Diagnostic Centers) – Global Forecast Till 2023

Market Scenario

The neurocutaneous syndrome is a group of neurologic disorders of brain, spine, and the peripheral nervous system. These diseases are lifelong conditions that may induce a tumor growth inside the skin, organs, skeletal bones, brain, and spinal cord.

These disorders are usually genetic and arise due to abnormal cell development at the embryo stage. The result is characterized by the development of tumors in various parts of the body. Even though some can be diagnosed at birth, most of them do not display symptoms until late. These syndromes cannot be cured, but various treatments can assist to manage the symptoms and any health concern. Lately, significant advances have been made by the use of DNA testing to confirm these syndromes in some people.

The three most common types of neurocutaneous syndromes are Tuberous sclerosis (TS), Neurofibromatosis (NF): Type I, Type II, and schwannomatosis, and Sturge-Weber disease.

Tuberous sclerosis (TS) is a non-cancerous growth that occurs in organs such as brain, eyes, kidneys, heart, lungs, bones, and skin. There is a 50% chance of children to develop TS if the parent is affected by it. Moreover, the Sturge-Weber Syndrome (SWS) causes malformations relating to the face, eye, and brain. It is estimated that about 1 in 20,000 to 50,000 live births may be affected with the Sturge-Weber syndrome.

Increasing government initiatives for ensuring the early diagnosis is supposed to be a significant driver of the market. Moreover, many guidelines are issued by government organizations to promote awareness related to effective prevention measures, globally. All these factors are expected to contribute to the market growth throughout the forecast period. Moreover, concerns regarding the safety of reprocessed instruments and stringent regulations for sterilization equipment manufacturers and service providers are factors hampering the market growth.

Global market for neurocutaneous disorders is expected to have a CAGR of approximately 6.5% during 2017 to 2023.

Intended Audience

- Clinical and diagnostic labs
- Pharmaceutical and biotechnology companies
- Regulatory bodies
- Medical device companies
- Healthcare providers
- Research and consulting firms
- Venture capitalists and investors

Figure 1: - Global Neurocutaneous Disorder Market Share, by Region
Segmentation

The global neurocutaneous disorder market has been segmented on the basis of type, diagnosis, treatment, and end-user.

On the basis of type, the global neurocutaneous disorder market can be segmented into Tuberous Sclerosis (TS), Neurofibromatosis (NF), Sturge-weber syndrome, Ataxia-Telangiectasia (A-T), Von Hippel-Lindau disease (VHL), and others.

Neurofibromatosis (NF) is further divided into Neurofibromatosis type 1 (NF1), Neurofibromatosis type 2 (NF2), and schwannomatosis. The Sturge-weber syndrome is divided into type-1, type-2, and type-3.

On the basis of diagnosis, the global neurocutaneous disorder market can be segmented into skull radiography, Magnetic Resonance Imaging (MRI), Computed Tomography (CT) scan, Electroencephalogram (EEG), genetic tests (blood testing), biopsy, and others.

On the basis of treatment, the global neurocutaneous disorder market can be segmented into medication, laser therapy, surgical procedures, and others.

Medication is further divided into antiepileptic, beta-antagonist eye drops, carbonic anhydrase inhibitors, adrenergic eye drops, miotic eye drops, and others. Surgical procedures are further divided into focal cortical resection, hemispherectomy, corpus callosotomy, trabeculectomy, filtration surgery, cyclocryotherapy, Vagal Nerve Stimulation (VNS), and others.

On the basis of end-user, the global neurocutaneous disorder market is segmented into hospitals and clinics, diagnostic centers, and others.

Regional Analysis

The global neurocutaneous disorder market consists of four regions, namely, the Americas, Europe, Asia Pacific, and the Middle East and Africa.

The Americas region accounted for the largest market share of the global neurocutaneous disorder market owing to the increasing awareness about genetic disorders along with the growing number of drug and medical service providers. As per the National Institute of Neurological Disorders and Stroke (NINDS) in 2017, Neurofibromatosis Type 1 (NF1) occurs in about 1 in 3,000 to 4,000 births in the U.S. This condition is a chromosomal disorder which is inherited from a parent. Moreover, Neurofibromatosis Type 2 (NF2) occurs less frequently, affecting about 1 in 25,000 births in the U.S.

The European neurocutaneous disorder market is the second largest market followed by Asia Pacific. The Asia Pacific region is expected to exhibit the fastest growth throughout the forecast period owing to the exceptional healthcare standards and infrastructure, rising healthcare expenditure, and growing presence of outsourcing organizations across this region. Moreover, the presence of various government organizations dedicated to improving the standards for neurocutaneous disorders is among the significant factors contributing towards the growth of the Asia Pacific region.

The Middle Eastern region is expected to grow at a steady pace owing to factors such as the extensive development of the healthcare infrastructure and increasing R&D activities in the healthcare sector.

Key Players

Some of the key players in the global neurocutaneous disorder market are Valeant Pharmaceuticals International, Inc. (U.S.), Allergan (U.S.), Syneron Medical Ltd (U.S.), Medtronic Plc (U.S.), Cutaera, Inc. (U.S.), St Jude Medical, Inc. (U.S.), Pfizer Inc. (U.S.), Novartis AG (Switzerland), Abbott Laboratories Inc. (U.S.), UCB S.A. (Belgium), Sanofi SA (France), Shire Plc (Ireland), F. Hoffmann-La Roche AG (Switzerland), Aleva Neurotherapeutics SA (Switzerland), Johnson & Johnson (U.S.), and others.
Contents:

Table of Contents:

Chapter 1. Report Prologue
Chapter 2. Market Introduction
  2.1 Definition
  2.2 Scope of the Study
  2.2.1 Research Objective
  2.2.2 Assumptions
  2.2.3 Limitations
Chapter 3. Research Methodology
  3.1 Introduction
  3.2 Primary Research
  3.3 Secondary Research
  3.4 Market Size Estimation
Chapter 4. Market Dynamics
  4.1 Drivers
  4.2 Restraints
  4.3 Opportunities
  4.4 Challenges
  4.5 Macroeconomic Indicators
  4.6 Technology Trends & Assessment
Chapter 5. Market Factor Analysis
  5.1 Porter’s Five Forces Analysis
    5.1.1 Bargaining Power of Suppliers
    5.1.2 Bargaining Power of Buyers
    5.1.3 Threat of New Entrants
    5.1.4 Threat of Substitutes
    5.1.5 Intensity of Rivalry
  5.2 Value Chain Analysis
  5.3 Investment Feasibility Analysis
  5.4 Pricing Analysis
Chapter 6. Global Neurocutaneous Disorder Market, by Type
  6.1 Introduction
  6.2 Tuberous Sclerosis (TS)
    6.2.1 Market Estimates & Forecast, 2017–2023
  6.3 Neurofibromatosis (NF)
    6.2.1 Neurofibromatosis Type 1 (NF1),
    6.2.2 Neurofibromatosis Type 2 (NF2),
    6.2.3 Schwannomatosis
  6.4 Sturge-Weber Syndrome Disease
    6.2.1 Type 1
6.2.2 Type 2
6.2.3 Type 3
6.5 Von Hippel-Lindau Disease (VHL)
6.5.1 Market Estimates & Forecast, 2017–2023
6.5 Ataxia-Telangiectasia (A-T)
6.5.1 Market Estimates & Forecast, 2017–2023
6.5 Others
6.5.1 Market Estimates & Forecast, 2017–2023

Chapter 7. Global Neurocutaneous Disorder Market, by Diagnosis
7.1 Introduction
7.2 Skull Radiography
7.2.1 Market Estimates & Forecast, 2017–2023
7.3 Magnetic Resonance Imaging (MRI)
7.3.1 Market Estimates & Forecast, 2017–2023
7.4 Computed Tomography (CT) Scan
7.4.1 Market Estimates & Forecast, 2017–2023
7.5 Electroencephalogram (EEG)
7.5.1 Market Estimates & Forecast, 2017–2023
7.6 Genetic Tests (blood testing)
7.6.1 Market Estimates & Forecast, 2017–2023
7.7 Biopsy
7.7.1 Market Estimates & Forecast, 2017–2023
7.6 Others
7.6.1 Market Estimates & Forecast, 2017–2023

Chapter 8. Global Neurocutaneous Disorder Market, by treatment
8.1 Introduction
8.2 Medication
8.2.1 Antiepileptic
8.2.2 Beta-Antagonist Eye Drops
8.2.3 Carbonic Anhydrase Inhibitors
8.2.4 Adrenergic Eye Drops
8.2.5 Miotic Eye Drops
8.2.6 Others
8.3 Laser Therapy
8.3.1 Market Estimates & Forecast, 2017–2023
8.4 Surgical Procedures
8.4.1 Focal Cortical Resection
8.4.2 Hemispherectomy
8.4.3 Corpus Callosotomy
8.4.4 Trabeculectomy
8.4.5 Filtration Surgery
8.4.6 Cyclocryotherapy
8.4.7 Vagal Nerve Stimulation (VNS)
8.4.8 Others

8.5 Others
8.5.1 Market Estimates & Forecast, 2017–2023

Chapter 9. Global Neurocutaneous Disorder Market, by End-User
9.1 Introduction
9.2 Hospital & Clinics
9.2.1 Market Estimates & Forecast, 2017–2023
9.3 Diagnostic Centers
9.3.2 Market Estimates & Forecast, 2017–2023
9.4 Others
9.4.1 Market Estimates & Forecast, 2017–2023

Chapter 10. Global Neurocutaneous Disorder Market, by Region
10.1 Introduction
10.2 Americas
10.2.1 North America
10.2.1.1 U.S.
10.2.1.1 Canada
10.2.2 South America
10.3 Europe
10.3.1 Western Europe
10.3.1.1 Germany
10.3.1.2 France
10.3.1.3 Italy
10.3.1.4 Spain
10.3.1.5 U.K.
10.3.1.6 Rest of Western Europe
10.3.2 Eastern Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 Republic of Korea
10.4.6 Rest of Asia Pacific
10.5 The Middle East & Africa
10.5.1 The Middle East
10.5.2 Africa
Chapter 10 Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

10.3.1 Key Developments

Chapter 11 Company Profiles

11.1 Valeant Pharmaceuticals International, Inc.

11.1.1 Company Overview

11.1.2 Types Overview

11.1.3 Financials

11.1.4 SWOT Analysis

11.2 Allergan

11.2.1 Company Overview

11.2.2 Types Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 Syneron Medical Ltd.

11.3.1 Company Overview

11.3.2 Types Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 Medtronic Plc

11.4.1 Company Overview

11.4.2 Types/Business Segment Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 Cutera, Inc.

11.5.1 Company Overview

11.5.2 Types Overview

11.5.3 Financial overview

11.5.4 Key Developments

11.6 St Jude Medical, Inc.

11.6.1 Company Overview

11.6.2 Types Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.7 Pfizer

11.7.1 Overview
11.7.2 Types Overview
11.7.3 Financials
11.7.4 Key Developments
11.7.5 SWOT Analysis
11.8 Others
Chapter 12 MRFR Conclusion
12.1 Key Findings
12.1.1 From CEO’s View Point
12.1.2 Unmet Needs of the Market
12.2 Key Companies to Watch
12.3 Prediction of the Neurocutaneous Disorder Industry
Chapter 13 Appendix
LIST OF TABLES
Table 1 Neurocutaneous Disorder Industry Synopsis, 2017–2023
Table 2 Neurocutaneous Disorder Market Estimates and Forecast, 2017–2023, (USD Million)
Table 3 Neurocutaneous Disorder Market, by Region, 2017–2023, (USD Million)
Table 4 Neurocutaneous Disorder Market, by Type, 2017–2023, (USD Million)
Table 5 Neurocutaneous Disorder Market, by Diagnosis, 2017–2023, (USD Million)
Table 6 Neurocutaneous Disorder Market, by Treatment, 2017–2023, (USD Million)
Table 7 Neurocutaneous Disorder Market, by End-User, 2017–2023, (USD Million)
Table 8 North America Neurocutaneous Disorder Market, by Type, 2017–2023, (USD Million)
Table 9 North America Neurocutaneous Disorder Market, by Diagnosis, 2017–2023, (USD Million)
Table 10 North America Neurocutaneous Disorder Market, by Treatment, 2017–2023, (USD Million)
Table 11 North America Neurocutaneous Disorder Market, by End-User, 2017–2023, (USD Million)
Table 12 U.S. Neurocutaneous Disorder Market, by Type, 2017–2023, (USD Million)
Table 13 U.S. Neurocutaneous Disorder Market, by Diagnosis, 2017–2023, (USD Million)
Table 14 U.S. Neurocutaneous Disorder Market, by Treatment, 2017–2023, (USD Million)
Table 15 US Neurocutaneous Disorder Market, by End-User, 2017–2023, (USD Million)
Table 16 Canada Neurocutaneous Disorder Market, by Type, 2017–2023, (USD Million)
Table 17 Canada Neurocutaneous Disorder Market, by Diagnosis, 2017–2023, (USD Million)
Table 18 Canada Neurocutaneous Disorder Market, by Treatment, 2017–2023, (USD Million)
Table 19 Canada Neurocutaneous Disorder Market, by End-User, 2017–2023, (USD Million)
Table 20 South America Neurocutaneous Disorder Market, by Type, 2017–2023, (USD Million)
Table 21 South America Neurocutaneous Disorder Market, by Diagnosis, 2017–2023, (USD Million)
Table 22 South America Neurocutaneous Disorder Market, by Treatment, 2017–2023, (USD Million)
Table 23 South America Neurocutaneous Disorder Market, by End-User, 2017–2023, (USD Million)
Table 24 Europe Neurocutaneous Disorder Market, by Type, 2017–2023, (USD Million)
Table 25 Europe Neurocutaneous Disorder Market, by Diagnosis, 2017–2023, (USD Million)
Table 26 Europe Neurocutaneous Disorder Market, by Treatment, 2017–2023, (USD Million)
Table 27 Europe Neurocutaneous Disorder Market, by End-User, 2017–2023, (USD Million)
Table 28 Western Europe Neurocutaneous Disorder Market, by Type, 2017–2023, (USD Million)
Table 29 Western Europe Neurocutaneous Disorder Market, by Diagnosis, 2017–2023, (USD Million)
Table 30 Western Europe Neurocutaneous Disorder Market, by Treatment, 2017–2023, (USD Million)
Table 31 Western Europe Neurocutaneous Disorder Market, by End-User, 2017–2023, (USD Million)
Table 32 Eastern Europe Neurocutaneous Disorder Market, by Type, 2017–2023, (USD Million)
Table 33 Eastern Europe Neurocutaneous Disorder Market, by Diagnosis, 2017–2023, (USD Million)
Table 34 Eastern Europe Neurocutaneous Disorder Market, by Treatment, 2017–2023, (USD Million)
Table 35 Eastern Europe Neurocutaneous Disorder Market, by End-User, 2017–2023, (USD Million)
Table 36 Asia Pacific Neurocutaneous Disorder Market, by Type, 2017–2023, (USD Million)
Table 37 Asia Pacific Neurocutaneous Disorder Market, by Diagnosis, 2017–2023, (USD Million)
Table 38 Asia Pacific Neurocutaneous Disorder Market, by Treatment, 2017–2023, (USD Million)
Table 39 Asia Pacific Neurocutaneous Disorder Market, by End-User, 2017–2023, (USD Million)
Table 40 Middle East & Africa Neurocutaneous Disorder Market, by Type, 2017–2023, (USD Million)
Table 41 Middle East & Africa Neurocutaneous Disorder Market, by Diagnosis, 2017–2023, (USD Million)
Table 42 Middle East & Africa Neurocutaneous Disorder Market, by Treatment, 2017–2023, (USD Million)
Table 43 Middle East & Africa Neurocutaneous Disorder Market, by End-User, 2017–2023, (USD Million)

LIST OF FIGURES
Figure 1 Research Process
Figure 2 Segmentation for Neurocutaneous Disorder Market
Figure 3 Segmentation Market Dynamics for Neurocutaneous Disorder Market
Figure 4 Global Neurocutaneous Disorder market Share, by Type 2016
Figure 5 Global Neurocutaneous Disorder market Share, by Diagnosis 2016
Figure 6 Global Neurocutaneous Disorder market Share, by Treatment 2016
Figure 7 Global Neurocutaneous Disorder market Share, by End-User, 2016
Figure 8 Global Neurocutaneous Disorder market Share, by Region, 2016
Figure 9 North America Neurocutaneous Disorder market Share, by Country, 2016
Figure 10 Europe Neurocutaneous Disorder market Share, by Country, 2016
Figure 11 Asia Pacific Neurocutaneous Disorder market Share, by Country, 2016
Figure 12 Middle East & Africa Neurocutaneous Disorder market Share, by Country, 2016
Figure 13 Global Neurocutaneous Disorder market: Company Share Analysis, 2016 (%)
Figure 14 Valeant Pharmaceuticals International, Inc.: Key Financials
Figure 15 Valeant Pharmaceuticals International, Inc. Segmental Revenue
Figure 16 Valeant Pharmaceuticals International, Inc.: Geographical Revenue
Figure 17 Allergan: Key Financials
Figure 18 Allergan: Segmental Revenue
Figure 19 Allergan: Geographical Revenue
Figure 20 Syneron Medical Ltd.: Key Financials
Figure 21 Syneron Medical Ltd.: Segmental Revenue
Figure 22 Syneron Medical Ltd.: Geographical Revenue
Figure 23 Medtronic Plc: Key Financials
Figure 24 Medtronic Plc: Segmental Revenue
Figure 25 Medtronic Plc: Geographical Revenue
Figure 26 Cutera: Key Financials
Figure 27 Cutera: Segmental Revenue
Figure 28 Cutera Geographical Revenue
Figure 29 St Jude Medical, Inc.: Key Financials
Figure 30 St Jude Medical, Inc.: Segmental Revenue
Figure 31 St Jude Medical, Inc.: Geographical Revenue
Figure 32 Pfizer Inc.: Key Financials
Figure 33 Pfizer Inc.: Segmental Revenue
Figure 34 Pfizer Inc.: Geographical Revenue